Skip to main content

Post-IPO Equity Life Science Companies

Explore 104 life science startups that raised post-ipo equity funding. Access verified founder contact information and fundraising data.

Total Companies
104
Total Funding
$587.7M
Avg Funding
$146.9M
Cities
4

Export 104 Post-IPO Equity Life Science Companies

Get founder emails, funding data, and company details in one CSV

Start Free Trial

Recently Funded Companies

Export
San Francisco, United States
$250.0M
raised

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

Oct 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

New York, United States
$154.0M
raised

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

Oct 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Berlin, Germany
$149.5M
raised

AtaiBeckley develops innovative mental health treatments that address significant unmet medical needs.

Oct 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$34.2M
raised

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

Oct 2022
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Showing 101 to 104 of 104 companies

Ready to Connect with Post-IPO Equity Life Science Startups?

Get verified founder emails, funding details, and company data for 104 post-ipo equity life science companies.

Get Started - Access Contact Information

Join thousands of sales teams, investors, and service providers using VCBacked

104 Life Science Post-IPO Equity Startups (September 2026) — Page 5 | VCBacked